NEW DRUG HISTORY
신약개발 History

코미팜의 신약개발 History입니다.

  • Confirmed an anti-cancer efficacy from In-vitro experiment and animal test at ONCOTEST Gmbh by Prof. Dr.H.H.Fiebig inf Friburg college of medicine in Germany.

2001~2003

  • Confirmed A safety from toxicity test at NOTOX(toxicity special agency) in the Netherlands.

2003~2004

  • Confirm an efficacy and safety from Phase I study on prostate cancer patient in Germany.

2004

  • Conducted a Phase 18 clinical test on lung cancer patients at Maryland College of Medicine in Baltimore, US and the results were presented at ASCO conference in USA on May, 2013

2005

  • Conducted several clinical tests in South Korea to confirm a safety and anti-cancer efficacy and the tests are in progress. (Attending institutions are Seoul National University Hospital, Severance Hospital, Asan Medical Center, Hanyang University Hospital, Sun-chun-hyang University hospital, Samsung Medical Center, Busan University Hospital and etc.

2006

  • Phase II A+B clinical test for cancer pain patients is in progress at the 10 hospitals in Australia now.

2008~2010

  • As we make progress, we hired third-party company, called COVANCE in New Jersey, US un order to check any missing points on the overall project from the objective perspective.

2011

  • KMFDS(Korea Ministry of Food Drug Safety) designated Komoniox project as the first "PAM NAVI", which is geared to proactively support the commercialization and globalization of the new drug.

2012

  • Kominox was approved for Special Access Scheme Category B by Therapeutic Goods Administration is Australia.

2016